Tildrakizumab OverviewTildrakizumab (trade name Ilumya (USA)/Ilumetri (European Union)) is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. In the United States, it is approved for the treatment of moderate-to-severe plaque psoriasis. Tildrakizumab was designed to block interleukin-23, a cytokine that plays an important role in managing the immune system and autoimmune disease. Contents 1 History 2 Approvals and indicati...
Read more Tildrakizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tildrakizumab
Recent Tildrakizumab Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 100mg/1ml
Other drugs which contain Tildrakizumab or a similar ingredient: (1 result)
- ILUMYA Tildrakizumab-asmn